Filing Analysis
Nutriband Inc. has entered into an amended three-year $5,000,000 credit line facility to replace a previous facility expiring in July 2026. The financing is intended to support the FDA approval process and commercial manufacturing of its lead product, AVERSA™ Fentanyl.
🚩 Red Flags
- The company is replacing a facility that was nearing expiration, indicating a continuous need for external debt financing to maintain operations/R&D.
📋 Key Facts
- Entered into an amended three-year $5,000,000 credit line facility on June 1, 2026.
- The new agreement replaces a previous $5,000,000 facility that was scheduled to expire on July 13, 2026.
- Drawdowns under the credit line bear interest at a rate of 7% per annum.
- The lender does not have the right to convert outstanding amounts into common stock.
- Funding is specifically earmarked for FDA approval and commercial scale manufacturing of AVERSA™ Fentanyl.
NutriBand Inc. filed a Form 8-K to furnish a press release dated March 30, 2026, under Regulation FD. The filing serves as a formal submission of public information previously disseminated by the company.
📋 Key Facts
- The reportable event occurred on March 30, 2026.
- The filing was submitted to the SEC on April 7, 2026.
- Item 7.01 (Regulation FD Disclosure) was the primary item triggered.
- The company is an emerging growth company listed on the Nasdaq Stock Market (NTRB, NTRBW).
- Exhibit 99.1 contains the press release text, though the content of the release was not detailed in the 8-K body.
Nutriband Inc. has terminated its agreement to sell its subsidiary, Pocono Pharmaceuticals, Inc., to Earth Vision Bio Inc. The termination follows the purchaser's failure to pay required late fees after missing a December 31, 2025, closing date.
🚩 Red Flags
- Failed asset sale: A planned divestiture/asset acquisition failed to close as scheduled.
- Counterparty default: The purchaser (Earth Vision Bio Inc.) defaulted on contractual late fee obligations.
- Cash flow implication: Loss of expected proceeds from the subsidiary sale may impact liquidity.
📋 Key Facts
- Termination of sale agreement for subsidiary Pocono Pharmaceuticals, Inc.
- Purchaser: Earth Vision Bio Inc.
- Reason for termination: Failure to pay applicable late fees following missed closing on December 31, 2025.
- The company has received $30,000 in late fees but no payments since January 21, 2026.
Nutriband, Inc. held its 2026 Annual Meeting of Stockholders on January 24, 2026. The meeting resulted in the election of seven directors and the approval of several key proposals, including an increase in authorized preferred stock.
🚩 Red Flags
- The doubling of authorized preferred stock (from 10M to 20M) can potentially lead to future dilution for existing common shareholders if used for capital raises.
📋 Key Facts
- Annual Meeting held on January 24, 2026, in Orlando, Florida.
- Seven director candidates were elected to one-year terms.
- Stockholders approved an amendment to the Articles of Incorporation to increase authorized Preferred Stock from 10,000,000 to 20,000,000 shares (86.25% in favor).
- Ratification of Sadler, Gibb & Associates, LLC as independent auditor for fiscal 2025 was approved.
- Two new directors were elected to the Board: Alessandro Puddu and Viorica Carlig.
Nutriband Inc. filed an 8-K to provide Regulation FD Disclosure, referencing a press release issued on December 29, 2025. The filing does not contain specific financial data or material event details within the provided text.
📋 Key Facts
- Filing date: December 30, 2025
- The report is filed pursuant to Item 7.01 (Regulation FD Disclosure)
- Reference made to a press release dated December 29, 2025
- Company is an emerging growth company
Nutriband Inc. filed an 8-K to provide Regulation FD Disclosure via a press release dated October 28, 2025. The filing serves as a placeholder for supplemental information rather than disclosing specific material transactions or structural changes in this text.
📋 Key Facts
- Filing date: October 28, 2025
- Registrant is an emerging growth company
- The filing includes Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits)
- Exhibits include a press release dated October 28, 2025
Nutriband Inc. reported the exercise of various outstanding stock options and warrants for the period between February 1, 2025, and July 31, 2025.
🚩 Red Flags
- Significant exercise of private investor warrants ($5M+) suggests recent large-scale financing or conversion activity by institutional/private parties.
📋 Key Facts
- Stock options covering 20,055 shares were exercised for a total price of $44,206.
- Public warrants (NTRBW) to purchase 47,076 shares were exercised for $302,699.
- Private investor warrants to purchase 778,041 shares were exercised for $5,002,804.
Nutriband Inc. completed a stock dividend of 3,008,643 shares of Series A Convertible Preferred Stock to existing shareholders on August 5, 2025. This follows recent board actions to significantly increase the authorized number of Series A Preferred shares from approximately 2.7 million to 10 million.
🚩 Red Flags
- Significant increase in authorized share count (from ~2.7M to 10M) creates potential for massive future dilution.
- The convertible nature of the Series A Preferred Stock linked to FDA approval introduces significant non-cash dilution risk upon a clinical/regulatory milestone.
📋 Key Facts
- Completed a stock dividend of 3,008,643 shares of Series A Preferred Stock on August 5, 2025.
- Dividend ratio: one share of Series A Preferred Stock for every four shares of common stock held as of July 25, 2025.
- Series A Preferred Stock is convertible into Common Stock upon FDA approval of the company's AVERSA™ transdermal technology products.
- The Board previously increased authorized Series A Preferred Stock from 2,788,678 to 10,000,000 shares via a Certificate of Correction filed July 21, 2025.
Nutriband Inc. has amended its Articles of Incorporation to authorize 2,788,678 shares of Series A Convertible Preferred Stock. The Board also approved a preferred stock dividend to existing common shareholders on a 1-for-4 basis.
🚩 Red Flags
- Potential dilution: The authorization and upcoming dividend of convertible preferred stock will significantly increase the total share count.
- Convertible features can lead to downward pressure on common stock price upon conversion (overhang).
📋 Key Facts
- Board approved amendment to Articles of Incorporation on July 9, 2025.
- Authorization of 2,788,678 shares of Series A Convertible Preferred Stock (par value $0.001).
- Preferred stock dividend: 1 share of Series A Preferred for every 4 shares of Common Stock owned.
- Record date for the preferred stock dividend is July 25, 2025.
- Series A Preferred Stock is convertible into one share of Common Stock per share upon FDA approval of transdermal pharmaceutical products based on AVERSA technology.
Nutriband Inc. has entered into an Associate Partnership agreement with Charlotte FC to increase brand visibility for its products, specifically mentioning 'AI Tape'. The partnership aims to leverage the local manufacturing presence in the Charlotte area.
📋 Key Facts
- Date of event: April 4, 2025
- Partner: Charlotte FC
- Agreement Type: Associate Partnership
- Primary Objective: Build visibility for brands such as AI Tape
- Strategic Context: Leveraging local manufacturing in the Charlotte area
Nutriband Inc. has signed an addendum to its Commercial Development and Clinical Supply Agreement with Kindeva Drug Delivery for its lead product, Aversa™ Fentanyl. The revised agreement formalizes an exclusive partnership involving shared development costs in exchange for milestone payments.
📋 Key Facts
- Addendum signed on February 13, 2025, regarding the Aversa™ Fentanyl product.
- Partner is Kindeva Drug Delivery, a global CDMO.
- Agreement structure involves shared development costs in exchange for milestone payments.
- The partnership focuses on Nutriband's abuse-deterrent transdermal technology.
Nutriband Inc. announced that the USPTO issued a Notice of Allowance for patent application 18/369,241 regarding its Aversa™ abuse deterrent transdermal technology on February 3, 2025.
📋 Key Facts
- Received Notice of Allowance from USPTO on February 3, 2025.
- Patent application 18/369,241 covers 'Abuse and Misuse Deterrent Transdermal Systems'.
- Technology is branded as Aversa™ abuse deterrent technology.
Nutriband, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on January 23, 2025. All seven director nominees were elected and all shareholder proposals, including auditor ratification and stock option plan approval, passed.
🚩 Red Flags
- High percentage of non-votes (32.94%) which may indicate shareholder apathy or lack of engagement in micro-cap governance.
📋 Key Facts
- Annual Meeting held on January 23, 2025, in Orlando, Florida.
- Seven directors (Gareth Sheridan, Serguei Melnik, Mark Hamilton, Stefani Mancas, Radu Bujoreanu, Irina Gram, and Sergei Glinka) were elected to one-year terms.
- Stockholders ratified the engagement of Sadler, Gibb & Associates, LLC as independent auditors for fiscal 2024.
- The 2024 Amended and Restated Stock Option Plan was approved by shareholders.
- Total votes cast represented approximately 67.06% of total outstanding shares (7,448,133 out of 11,106,185).
- Non-votes accounted for 32.94% of the total outstanding shares.
Nutriband Inc. announced the successful completion of registration requirements to extend its 'Abuse and Misuse Deterrent Transdermal Systems' patent (AVERSA™ technology) into Macao on December 27, 2024.
📋 Key Facts
- Patent title: 'Abuse and Misuse Deterrent Transdermal Systems'.
- Technology name: AVERSA™ abuse deterrent transdermal technology.
- Jurisdiction of extension: Macao.
- Filing date for the event: December 27, 2024.
Nutriband Inc. announced that the Chinese National Intellectual Property Administrant (CNIPA) has fully issued a patent titled 'Abuse and Misuse Deterrent Transdermal System' related to its AVERSA™ technology.
📋 Key Facts
- Patent Title: 'Abuse and Misuse Deterrent Transdermal System'
- Issuing Body: Chinese National Intellectual Property Administrant (CNIPA)
- Technology Association: Related to the Company's lead technology, AVERSA™
- Filing Date: October 31, 2024
Nutriband Inc. announced a share repurchase program on September 16, 2024, authorizing the company to buy back up to $1,000,000 of its common stock.
📋 Key Facts
- Announcement date: September 16, 2024
- Repurchase authorization amount: Up to $1,000,000 of common stock
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure)
NutriBand Inc. filed an amendment to its 8-K to report the issuance of common stock and warrants resulting from a debt conversion. The company converted $300,000 of principal and interest held by TII Jet Services LDA into equity.
🚩 Red Flags
- Debt-for-equity conversion indicates potential liquidity constraints or use of debt to settle obligations.
- The issuance of warrants (double the number of converted shares) represents significant future dilution for existing shareholders.
📋 Key Facts
- Conversion of $300,000 in outstanding principal and accrued interest of the Creditline Promissory Note.
- Issuance of 76,230 shares of Common Stock at a conversion price of $4.00 per share.
- Issuance of 152,460 common stock warrants to TII Jet Services LDA.
- Warrants expire on May 14, 2029, with an exercise price of $6.43 per share.
- The filing is an amendment (8-K/A) correcting the omission of warrant details from a previous filing dated May 21, 2024.
Nutriband Inc. announced the conversion of $300,000 of outstanding principal and accrued interest from a Creditline Promissory Note into 76,230 shares of common stock.
🚩 Red Flags
- Debt conversion into equity can lead to dilution for existing shareholders.
📋 Key Facts
- Conversion date: May 14, 2024
- Holder: TII Jet Services LDA
- Amount converted: $300,000 (principal and accrued interest)
- Shares issued: 76,230 shares of Common Stock
- Conversion price: $4.00 per share
Nutriband Inc. announced the appointment of Sergei Glinka to its Board of Directors on May 15, 2024.
📋 Key Facts
- Sergei Glinka appointed as a director effective May 15, 2024.
- Mr. Glinka has served as Commercial Manager of TG Biochemicals Limited (Cyprus) since 2019.
- Mr. Glinka is a board member of GST Investments OÜ (Estonia).
Nutriband Inc. completed an $8.4 million equity financing on April 19, 2024, involving the issuance of 2.1 million units to European investors via Regulation S.
🚩 Red Flags
- Potential future dilution due to warrants representing 4.2 million shares upon exercise (2:1 ratio)
- Warrants are exercisable in cash only, which provides immediate capital but increases share count upon exercise
📋 Key Facts
- Total offering amount: $8,400,000
- Units issued: 2,100,000 Units at $4.00 per Unit
- Each unit contains one share of common stock and one warrant to purchase two shares
- Warrant exercise price: $6.43 (cash only)
- Warrant expiration date: April 19, 2029
- Offering conducted under Regulation S for non-U.S. resident investors
Nutriband Inc. reported the issuance of stock options and warrants to several key executives and a consultant on March 20, 2024. Additionally, the Board approved an amendment to the 2021 Employee Stock Option Plan to significantly increase the number of shares available for issuance.
🚩 Red Flags
- Related-party transactions: Significant equity awards granted directly to top management (CEO, President, CFO, COO, CSO).
- Potential dilution: The amendment to the Employee Stock Option Plan increases the share pool by over 60% (from 875k to 1.4M shares).
📋 Key Facts
- Issuance of stock options to CEO Gareth Sheridan (97,500 shares) at $2.61/share.
- Issuance of stock options to President Serguei Melnik (97,500 shares) at $2.61/share.
- Issuance of stock options to CFO Gerald Goodman (75,000 shares) and COO Alan Smith (70,000 shares) at $2.37/share.
- Issuance of a common stock purchase warrant to Counsel Michael Paige for 15,000 shares at $2.37/share.
- Amendment to the 2021 Employee Stock Option Plan increases available shares from 875,000 to 1,400,000.
Nutriband, Inc. held its 2023 Annual Meeting of Stockholders on January 21, 2024. The meeting resulted in the election of six directors and the ratification of Sadler, Gibb & Associates, LLC as the independent audit firm for fiscal 2023.
📋 Key Facts
- Annual Meeting held on January 21, 2024, in Orlando, Florida.
- Six directors were elected to one-year terms: Gareth Sheridan, Serguei Melnik, Mark Hamilton, Radu Bujoreanu, Stefani Mancas, and Irina Gram.
- Stockholders ratified the engagement of Sadler, Gibb & Associates, LLC as independent auditors for fiscal 2023 with 5,720,198 votes in favor.
- Advisory 'Say on Pay' regarding executive compensation was approved (5,299,717 votes for).
- The frequency of the 'Say on Pay' vote was also subject to advisory approval.
Nutriband Inc. filed an 8-K to provide Regulation FD Disclosure via a press release dated January 4, 2024. The filing serves as a formal mechanism to disseminate information previously released or intended for public consumption.
📋 Key Facts
- The report is being filed under Item 7.01 (Regulation FD Disclosure).
- A press release dated January 4, 2024, is attached as Exhibit 99.1.
- The company is an emerging growth company.
- Securities involved include Common Stock (NTRB) and Warrants (NTRBW) listed on Nasdaq.